ns5a

NS5A-IN-2 (Compound 33) is a potent NS5A inhibitor with remarkable efficacy against HCV genotype 1b, increased activity against genotype 3a (GT 3a), and significant metabolic stability [1].

NS5A-IN-1 is a proagent of the HCV NS5A inhibitor, Pibrentasvir (ABT-530).

NS5A-IN-3 (Compound 15) is a potent NS5A inhibitor with high efficacy against HCV genotype 1b, enhanced activity towards genotype 3a (GT 3a), and substantial metabolic stability. It exhibits superior resistance barrier compared to daclatasvir in genotype 1b [1].

NS5A-IN-4 (Compound 1.12) is a pan-genotypic, orally active inhibitor of the hepatitis C virus (HCV) NS5A, with IC50 values of 1.2, 2296, 4.6, 362, 10.3, and 693 pM against genotypes gT1b, gT1a, gT2a, gT3a, gT4a, and gT5a, respectively [1].

ABT530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6.

MK-8325 is a potent and orally available HCV NS5A inhibitor with replicative activity against a wide range of genotypes.MK-8325 has demonstrated bioavailability in in vitro and in vivo assays and has a favorable overall ADME profile.

Ruzasvir (MK-8408) is a novel and potent pan-genotypic inhibitor of hepatitis C virus NS5A with antiviral activity.

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Velpatasvir (GS-5816), also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.

Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Elbasvir (MK-8742) is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

Samatasvir (ATOLIHZIXHZSBA-BTSKBWHGSA-N) is a pan-genotypic inhibitor of the HCV non-structural protein 5A.

DBPR-110 is a nonstructural protein 5A (NS5A) inhibitor. DBPR-110 reduced the reporter expression of the HCV1b replicon with a EC(50) and a selective index value of 3.9 ± 0.9 pM and >12,800,000, respectively. DBPR-110 reduced HCV2a replicon activity with

GSK2818713 is a novel inhibitor of the Hepatitis C NS5A replication complex.

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM) with a superior pan-genotypic profile, good pharmacokinetic properties, and favorable liver uptake.

Ledipasvir-d6 is a deuterated compound of Ledipasvir. Ledipasvir has a CAS number of 1256388-51-8. Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.

MK-4882 is an effective inhibitor of HCV NS5A.

Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.

Ledipasvir (acetone) (GS-5885 acetone) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Ravidasvir, also known as PPI-668 and ASC16, is a second-generation oral medication that exhibits potent and selective inhibition specifically targeting the nonstructural protein 5A (NS5A) of the Hepatitis C virus (HCV).

Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the HCV NS5B RNA-dependent RNA polymerase, inhibiting recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 (IC50 < 28 nM).

Odalasvir is a novel NS5A inhibitor for the treatment of hepatitis C.